clinical trial · NCT05838521
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Yale University·phase2·recruiting·n = 20
Cervical CancerSacituzumab govitecan
brief summary
This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.
started
Jun 2, 2023
primary completion
Dec 1, 2026
completion
Dec 1, 2028
last updated
Jul 27, 2026
detailed description
This is an open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in subjects with recurrent or persistent cervical cancer.
official title
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate in Patients With Recurrent or Persistent Cervical Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol